<HashMap><database>ecrin-mdr-crc</database><scores/><additional><omics_type>Clinical</omics_type><study_start_year>2012</study_start_year><condition>Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, and Head &amp; Neck Cancer</condition><condition>Sarcoma</condition><disease>Sarcoma</disease><disease>Triple Negative Breast, Prostate, Colorectal, Gastric, Ovarian, Pancreatic, Esophageal, Soft Tissue Sarcoma, And Head &amp; Neck Cancer</disease><study_type>Observational</study_type><full_dataset_link>https://newmdr.ecrin.org/Study/2130178</full_dataset_link><location>United States</location><study_start_month>7</study_start_month><repository>ECRIN MDR</repository><study_status>Terminated</study_status></additional><is_claimable>false</is_claimable><name>Study of 124I-NM404 in Advanced Solid Malignancies</name><description>The purpose of this study is to assess the use of investigational compound 124I-NM404 for accurate detection and characterization of a wide variety of solid primary and metastatic malignancies anywhere in the body.</description><dates><creation>2012-07-15</creation></dates><accession>2130178</accession><cross_references><ClinicalTrials___gov>NCT01662284</ClinicalTrials___gov></cross_references></HashMap>